Benzodiazepine exposure in pregnancy and risk of major malformations: A critical overview

General Hospital Psychiatry

Volumn 35, Issue 1, 2013, Pages 3-8

  Bellantuono, Cesario ^a   Tofani, Stefania ^a   Di Sciascio, Guido ^b   Santone, Giovanni ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Benzodiazepines; Major malformations; Pregnancy

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BROMAZEPAM; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; LORAZEPAM; MEDAZEPAM; NITRAZEPAM; PROMETHAZINE;

ANUS ATRESIA; ARTICLE; CARDIOVASCULAR MALFORMATION; CONGENITAL MALFORMATION; DEPRESSION; DIGESTIVE SYSTEM MALFORMATION; DOSE RESPONSE; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; HYPEREMESIS GRAVIDARUM; LOW BIRTH WEIGHT; MENTAL DISEASE; MICROCEPHALY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; BENZODIAZEPINES; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK; TERATOGENS;

EID: 84872409757     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.09.003     Document Type: Article

References (43)

1. Marchetti F., Romero M., Bonati M., Tognoni G. Use of psychotropic drug during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Eur J Clin Pharmacol 1993, 43:495-501. the Collaborative Group on Drug Use in Pregnancy (CGDUP).
2. Lacroix I., Hurault C., Sarramon M.F., et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009, 65:839-846.
3. Andrade S.E., Gurwitz J.H., Davis R.L., et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004, 191:398-407.
4. Egen-Lappe V., Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004, 60:659-666.
5. Dolovich L.R., Addis A., Vaillancourt J.M.R., Power J.D.B., Koren G., Einarson T.R. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998, 317:839-843.
6. Enato E., Moretti M., Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can 2011, 33:46-48.
7. Rockenbauer M., Olsen J., Czeizel A.E., Pedersen L., Sørensen H.T. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology 2001, 12:461-466. and the EUROMAP group.
8. Källén B.A.J. Methodological issues in the epidemiological study of teratogenicity of drugs. Congenit Anom 2005, 45:44-51.
9. Gerlich M.G., Rehm J. Recall bias in case-crossover designs studying the potential influence of alcohol consumption. J Stud Alcohol Drugs 2010, 71:619.
10. Iqbal M.M., Sobhan T., Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002, 53:39-49.
11. Eros E., Czeizel A.E., Rockenbauer M., Sorensen H.T., Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002, 101:147-154.
12. Wikner B.N., Stiller C.O., Bergman U., Asker C., Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:1203-1210.
13. Oberlander T.F., Warburton W., Misri S., Riggs W., Aghajanian J., Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008, 83:68-76.
14. Oberlander T.F., Grunau R.E., Fitzgerald C., et al. Prolonged prenatal psychotropic exposure alters neonate acute pain response. Pediatr Res 2002, 51:443-453.
15. Mortensen J.T., Olsen J., Larsen H., et al. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 2003, 18:769-771.
16. Oberlander T.F., Misri S., Fitzgerald C.E., Kostaras X., Rurak D., Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004, 65:230-237.
17. Wikner B.N., Stiller C.O., Källén B., Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf 2007, 16:988-994.
18. Calderon-Margalit R., Qiu C., Ornoy A., Siscovick D.S., Williams M.A. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 2009, 201:579e1-579e8.
19. Bonnot O., Vollset S.E., Godet P.F., D'Amato T., Robert E. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. J Clin Psychopharmacol 2001, 21:456-458.
20. Czeizel A.E., Eros E., Rockenbauer M., Sorensen H.T., Olsen J. Short-term oral diazepam treatment during pregnancy: a population-based teratological case-control study. Clin Drug Investig 2003, 23:451-462.
21. Czeizel A.E., Rockenbauer M., Sorensen H.T., Olsen J. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicol Teratol 2004, 26:593-598.
22. Lin A.E., Peller A.J., Westgate M.N., Houde K., Franz A., Holmes L.B. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol 2004, 70:534-536.
23. Kjaer D., Horvath-Puho E., Christensen J., et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf 2007, 16:181-188.
24. Gidai J., Acs N., Bánhidy F., Czeizel A.E. No association found between use of very large doses of diazepam by 112 pregnant women for a suicide attempt and congenital abnormalities in their offspring. Toxicol Ind Health 2008, 24:29-39.
25. Gidai J., Acs N., Bánhidy F., Czeizel A.E. A study of the teratogenic and fetotoxic effects of large doses of chlordiazepoxide used for self-poisoning by 35 pregnant women. Toxicol Ind Health 2008, 24:41-51.
26. Gidai J., Acs N., Bánhidy F., Czeizel A.E. An evaluation of data for 10 children born to mothers who attempted suicide by taking large doses of alprazolam during pregnancy. Toxicol Ind Health 2008, 24:53-60.
27. Gidai J., Acs N., Bánhidy F., Czeizel A.E. A study of the effects of large doses of medazepam used for self-poisoning in 10 pregnant women on fetal development. Toxicol Ind Health 2008, 24:61-68.
28. Almgren M., Källén B., Lavebratt C. Population-based study of antiepileptic drug exposure in utero-influence on head circumference in newborns. Seizure 2009, 18:672-675.
29. Tasci Y., Demir B., Dilbaz S., Haberal A. Use of diazepam for hyperemesis gravidarum. J Matern Fetal Neonatal Med 2009, 22:353-356.
30. Gidai J., Acs N., Bánhidy F., Czeizel A.E. Congenital abnormalities in children of 43 pregnant women who attempted suicide with large dose of nitrazepam. Pharmacoepidemiol Drug Saf 2010, 19:175-182.
31. Buhimschi C.S., Weiner C.P. Medications in pregnancy and lactation. Part 1. Teratology. Obstet Gynecol 2009, 113:166-188.
32. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 2011, 123:266-275.
33. Diav-Citrin O., Ornoy A. Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?. Obstet Gynecol Int 2012, 2012:698947.
34. American College of Obstetricians and Gynecologists Use of psychiatric drugs during pregnancy and lactation. ACOG Practice Bulletin 92. Obstet Gynecol 2008, 111:1001-1020.
35. Yonkers K.A., Wisner K.L., Stewart D.E., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009, 114:703-713.
36. Vesga-López O., Blanco C., Keyes K., Olfson M., Grant B.F., Hasin D.S. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 2008, 65:805-815.
37. Conde A., Figueiredo B., Tendais I., et al. Mother's anxiety and depression and associated risk factors during early pregnancy: effects on fetal growth and activity at 20-22 weeks of gestation. J Psychosom Obstet Gynaecol 2010, 31:70-82.
38. Regan L., Braude P.R., Trembath P.L. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989, 299:541-545.
39. Blohm F., Fridén B., Milsom I. A prospective longitudinal population-based study of clinical miscarriage in an urban Swedish population. BJOG 2008, 115:176-183.
40. Czeizel A.E., Tomcsik M., Timar L. Teratologic evaluation of 178 infants born to mothers who attempted suicide by drugs during pregnancy. Obstet Gynecol 1997, 90:195-201.
41. McClure C.K., Patrick T., Katz K.D., Kelsey S.F., Weiss H.B. Birth outcomes following self-inflicted poisoning during pregnancy, California, 2000 to 2004. JOGNN 2011, 40:292-301.
42. Centre for International Clearinghouse for Birth Defects Surveillance and Research Annual report 2010 with data for 2008 2010, Centre for International Clearinghouse for Birth Defects Surveillance and Research, Rome, Italy.
43. Tofani S, Bellantuono C. DeGra Center: Centro Specialistico per il Trattamento della Depressione in Gravidanza e Puerperio [The Center for Depression in Pregnancy and Postpartum at the Psychiatric Unit of the United Hospitals of Ancona-University of Marche, Italy]. Postgraduate thesis, unpublished data 2012. http://www.degradatabase.it.